CAMBRIDGE, Mass., Sept. 3, 2021 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a precision therapy company focused on
genomically defined cancers, rare diseases and cancer
immunotherapy, today announced that, effective on September 1, 2021, the Compensation Committee of
Blueprint Medicines' Board of Directors granted non-qualified stock
options to purchase an aggregate of 23,720 shares of its common
stock and an aggregate of 11,858 restricted stock units (RSUs) to
12 new employees under Blueprint Medicines' 2020 Inducement
Plan.
The 2020 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously an employee or
non-employee director of Blueprint Medicines, as an inducement
material to such individual's entering into employment with
Blueprint Medicines, pursuant to Rule 5635(c)(4) of the NASDAQ
Listing Rules.
The options have an exercise price of $96.13 per share, which is equal to the closing
price of Blueprint Medicines' common stock on September 1, 2021. Each option will vest as to
25% of the shares underlying such option on the first anniversary
of the grant date and as to an additional 1/48th of the shares
underlying the option monthly thereafter, in each case,
subject to each such employee's continued employment on each
vesting date. Each RSU will vest as to 25% of the shares underlying
the RSU award on the first anniversary of the grant date and as to
an additional 25% of the shares underlying the RSU award annually
thereafter, subject to each such employee's continued employment on
each vesting date. The options and RSUs are subject to the terms
and conditions of Blueprint Medicines' 2020 Inducement Plan, and
the terms and conditions of the stock option and RSU agreement
covering the grant.
About Blueprint Medicines
Blueprint Medicines is a
global precision therapy company that invents life-changing
therapies for people with cancer and hematologic disorders.
Applying an approach that is both precise and agile, we create
medicines that selectively target genetic drivers, with the goal of
staying one step ahead across stages of disease. Since 2011, we
have leveraged our research platform, including expertise in
molecular targeting and world-class drug design capabilities, to
rapidly and reproducibly translate science into a broad pipeline of
precision therapies. Today, we are delivering approved medicines
directly to patients in the United
States and Europe, and we
are globally advancing multiple programs for genomically defined
cancers, systemic mastocytosis, and cancer immunotherapy. For more
information, visit www.BlueprintMedicines.com and follow us on
Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301368684.html
SOURCE Blueprint Medicines Corporation